Teva Appoints Richard Francis As CEO On Retirement Of Kåre Schultz

(RTTNews) – Teva Pharmaceutical Industries Ltd. (TEVA) Monday said it has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023, following retirement of current CEO Kåre Schultz.

Schultz will retire from his current position, effective December 31, 2022, the company said.

Francis with more than two and a half decades of experience as a pharmaceutical executive, is currently serving as CEO of Syncona’s portfolio companies, AAV gene therapy company, Purespring Therapeutics, and Forcefield Therapeutics.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link

You May Also Like

About the Author:

Leave a Reply

Your email address will not be published. Required fields are marked *